In addition, blood examination revealed a positive expression for WT1 mRNA before imatinib therapy which turned negative after remission, suggesting that WT1 mRNA level is a possible marker that could distinguish CEL from HES. This evidence concerns the gene WT1 and hypereosinophilic syndrome.